New shot shields thousands of babies from severe RSV
NCT ID NCT06325332
First seen Nov 06, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tested how well a single dose of BEYFORTUS (nirsevimab) protects infants from serious RSV infections that require a doctor visit. Nearly 50,000 babies were followed during their first RSV season. The goal was to see if the shot reduces hospitalizations, emergency visits, and other RSV-related illnesses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kaiser Permanente Northern California: Site number 0001
Oakland, California, 94612, United States
Conditions
Explore the condition pages connected to this study.